Amyloid imaging with 18 F-labeled radiotracers will allow widespread use, facilitating research, diagnosis, and therapeutic development for Alzheimer disease. The purpose of the study program was to compare cortical amyloid deposition using 18 F-florbetaben and PET in controls and subjects with mild cognitive impairment (MCI), frontotemporal lobar degeneration (FTLD), dementia with Lewy bodies (DLB), vascular dementia (VaD), Parkinson disease (PD), and Alzheimer disease (AD). Methods: One hundred nine subjects in 3 clinical studies at Austin Health were reviewed: 32 controls, 20 subjects with MCI, and 30 patients with AD, 11 with FTLD, 7 with DLB, 5 with PD, and 4 with VaD underwent PET after intravenous injection of 300 MBq of 18 F-florbetaben. Standardized uptake value ratios (SUVR) using the cerebellar cortex as a reference region were calculated between 90 and 110 min after injection. Results: When compared with the other groups, AD patients demonstrated significantly higher SUVRs (P , 0.0001) in neocortical areas. Most AD patients (96%) and 60% of MCI subjects showed diffuse cortical 18 F-florbetaben retention. In contrast, only 9% of FTLD, 25% of VaD, 29% of DLB, and no PD patients and 16% of controls showed cortical binding. Although there was a correlation between Mini Mental State Examination and b-amyloid burden in the MCI group, no correlation was observed in controls, FTLD or AD. Conclusion: 18 F-florbetaben had high sensitivity for AD, clearly distinguished patients with FTLD from AD, and provided results comparable to those reported with 11 C-Pittsburgh Compound B in a variety of neurodegenerative diseases.
b-amyloid (Ab) imaging with PET permits in vivo assessment of Ab deposition in the brain, providing an important new tool for the evaluation of the causes, diagnosis, and future treatment of dementias for which Ab may play a role (1) . Studies with 11 C-Pittsburgh Compound B ( 11 CPiB), the most specific and most widely used PET Ab ligand, indicate that Ab imaging may allow earlier diagnosis of Alzheimer disease (AD) pathology (2-4) and accurate differential diagnosis of the dementias (2, 5, 6 ). 11 C-PiB studies show robust cortical binding in almost all AD patients (2, 3) and correlate well with reduction in cerebrospinal fluid Ab 42 (7) . Binding is associated with cerebral atrophy as measured by MRI (8) and with episodic memory impairment in apparently healthy elderly individuals and in subjects with mild cognitive impairment (MCI) (9) . Increased 11 C-PiB binding may also be predictive of conversion of MCI to AD (10) .
After recent advances in imaging and cerebrospinal fluid analysis, it has been proposed that the research criteria for the diagnosis of probable AD should be revised to allow earlier diagnosis and therapeutic intervention. These proposals have argued that when there is a clear history of progressive cognitive decline, objective evidence from psychometric tests of episodic memory impairment, and characteristic abnormalities in the cerebrospinal fluid or neuroimaging studies such as amyloid imaging, dementia might not be required for the diagnosis of probable AD (11, 12) . Thus, as the criteria for the diagnosis of AD evolve, Ab imaging is likely to have an increasingly important role in clinical practice provided it is accessible and affordable (13) .
Unfortunately, the 20-min radioactive decay half-life of 11 C limits the use of 11 C-PiB to centers with an on-site cyclotron and 11 C radiochemistry expertise. Consequently, access to 11 C-PiB PET is restricted, and the high cost of studies is prohibitive for routine clinical use. To overcome these limitations, several tracers labeled with 18 F (half-life, 110 min), permitting centralized production and regional distribution, were synthesized and tested (13) (14) (15) (16) (17) .
We reported in the first human study with 18 F-florbetaben ( 18 F-BAY94-9172) (14) a robust separation in 15 AD patients from 15 healthy age-matched controls and 5 frontotemporal lobar degeneration (FTLD) patients both by visual image interpretation and simple quantitative measures from a scan that requires 20 min of PET camera time. The continuation of this study and the additional studies aim at extending those initial evaluations into other dementing and nondementing neurodegenerative diseases and compare the results with clinical and cognitive features.
MATERIALS AND METHODS

Study Participants
The studies were approved by the Austin Health Human Research Ethics Committee. Written informed consent was obtained from all subjects before participation and also from the next of kin or caregiver for the patients with dementia. Participants were clinically classified by consensus between a neurologist and a neuropsychologist. Thirty-two controls; 20 patients meeting criteria for MCI, with 80% of them being classified as amnestic MCI (18) (23) were studied. Subjects with probable dementia or MCI were recruited from the Austin Health Memory Disorders Clinic if they met the inclusion and exclusion criteria and were willing to participate. Participants fulfilling clinical criteria for PD were recruited from movement disorders clinics. Controls were recruited by advertisement in the community. Data from half of the controls, half of the AD, and FTLD patients included into the first human study have appeared in a previous report (14) .
All subjects were aged over 55 y, spoke fluent English, and had completed at least 7 y of education. No subjects had a history or physical or imaging findings of other neurologic or psychiatric illness, current or recent drug or alcohol abuse or dependence, or any significant other disease or unstable medical condition.
Participants were administered the Mini Mental State Examination (MMSE), the Clinical Dementia Rating (CDR), and a battery of neuropsychologic tests to ensure patients fulfilled diagnostic criteria for AD or normality. Controls were excluded if any score fell below 1 SD of the published mean for that test. MRI and psychometric examination were completed within 4 wk of the 18 F-florbetaben scan.
As previously reported (14) , safety monitoring consisted of hematology and biochemistry assessments, clinical observation, and intermittent measurement of vital signs for 3 h commencing immediately before tracer injection. Clinical and laboratory evaluation was repeated 1 wk after the scan for comparison. Participants were asked about possible adverse events at 24 h and 1 wk after injection.
Image Acquisition
MRI consisted of a 3-dimensional T1-weighted magnetizationprepared rapid gradient-echo scan (repetition time, 2,300 ms; echo time, 2.98 ms; and flip angle, 9°) used for screening and coregistration with the PET images. The image size was 160 · 240 · 256 voxels, with a voxel dimension of 1.2 · 1 · 1 mm in the sagittal, coronal, and axial directions, respectively. All highresolution MR images were obtained on a 3-T Magnetom Trio scanner (Siemens). 18 F-florbetaben was radiolabeled in the Centre for PET, Austin Health, as previously described (14) . The final administered product contained 1.6 6 1.2 mg of florbetaben, with a specific activity (SA) of 105 6 74 GBq/mmol and a radiochemical purity higher than 95%. PET scans were acquired on a 3-dimensional Phillips Allegro scanner in the Austin Health Centre for PET. A transmission scan using a rotating 137 Cs source was obtained for attenuation correction immediately before the emission scan. Although some subjects underwent a dynamic acquisition scan for 60 min after injection of 300 MBq of 18 F-florbetaben, all participants underwent a static scan at 90-110 min after injection. Images were reconstructed using a 3-dimensional row-action maximum-likelihood algorithm.
To test the robustness of the results and potential pharmacologic effects of florbetaben, a subgroup of 8 controls and 8 AD patients underwent a second PET scan within 4 wk (median, 3 wk), for which 50 mg of florbetaben were added to the end-of-synthesis solution. Thus, the administered final product contained 1.9 6 0.9 mg of florbetaben with an SA of 58.4 6 27.5 GBq/mmol for the high-SA study and 49.4 6 3.1 mg of florbetaben with an SA of 1.9 6 0.2 GBq/mmol for the low-SA study; in both studies, radiochemical purity was higher than 95%.
Image Analysis
PET images were coregistered with each individual's MR image using SPM5 (24) . Regions of interest (ROIs) were then drawn on the individual MR image and transferred to the coregistered PET images (Fig. 1) . Mean radioactivity values were obtained from ROIs for cortical, subcortical, and cerebellar regions. White-matter ROIs were placed at the centrum semiovale, and the cerebellar regions were placed over the cerebellar cortex, with care taken to avoid white matter (Fig. 1) . In 4 patients, MR images could not be obtained and ROIs were drawn directly onto the PET images by an operator unaware of the clinical status of the patients. No correction for partial volume was applied to the PET data.
Standardized uptake values (SUVs), defined as the decaycorrected brain radioactivity concentration, normalized for injected dose and body weight, were calculated for all regions. These were then used to derive the SUV ratio (SUVR) referenced to the cerebellar cortex, a region relatively unaffected by dense Ab plaques in sporadic AD, at 90 min after injection, when the ratio of binding in the neocortex to that in the cerebellar cortex reaches apparent steady-state (14) . Neocortical Ab burden was expressed as the average SUVR of the area-weighted mean for the following cortical ROIs: frontal (consisting of dorsolateral prefrontal, ventrolateral prefrontal, and orbitofrontal regions), superior parietal, lateral temporal, lateral occipital, and anterior and posterior cingulate.
To identify an SUVR cutoff, a hierarchical cluster analysis was performed on the controls that yielded a cutoff for high or low neocortical SUVR of 1.4, similar to the cutoff values used in previous PiB PET studies (8, 25) .
The 18 F-florbetaben 90-to 110-min SUVR images were also visually graded on a Philips workstation and displayed with a rainbow color scale. The color scale was adjusted so that cerebellar white matter was yellow, as previously described for reading 11 CPiB images (26) . Two nuclear medicine physicians with experience in interpretation of 11 C-PiB scans and unaware of diagnosis and all other clinical information classified the 18 F-florbetaben images as normal, possible Ab deposition, or probable Ab deposition based on the presence (green to red) or absence (blue to black) of 18 Fflorbetaben binding in the cerebral cortex. After grouping together possible and probable from the visual assessment, a 2 · 2 contingency analysis was used to determine the test sensitivity and specificity of both semiquantitative and visual analysis of 18 Fflorbetaben in differentiating probable AD patients from controls.
Statistical Evaluation
Normality of distribution was tested using the Shapiro-Wilk test and visual inspection of variable histograms. Statistical evaluations between groups were performed using a Tukey-Kramer honestly significant difference test to establish differences between group means and using a Dunnet test to compare each group with controls. Effect size was measured with Cohen d. Categoric differences were evaluated using Fisher exact test. Pearson product-moment correlation analyses were conducted between 18 F-florbetaben SUVR and clinical features. Given the association between Ab deposition and age observed with 11 CPiB (27) , all comparisons and correlations were corrected for age effects. Receiver-operating-characteristic (ROC) curve analysis was applied to assess the robustness of the different parameters to discriminate between AD patients and controls. Data are presented as mean 6 SD unless otherwise stated.
RESULTS
Participants' demographics are detailed in Table 1 . One hundred nine subjects were recruited and studied between September 2006 and June 2010. All recruited subjects completed the respective studies and are included in the evaluation. There were no significant differences between the different groups and controls in age or sex. Significantly lower MMSE scores were observed in the AD, DLB, and FTLD groups (Table 1) . Of the 109 participants, 32 (29%) were classified as controls (MMSE, 29.6 6 0.7), 30 (28%) fulfilled criteria for probable AD (MMSE, 22.8 6 3.7), 20 (18%) fulfilled criteria for MCI (MMSE, 27.4 6 1.9, 80% amnestic type), 11 (10%) fulfilled criteria for FTLD (MMSE, 24.5 6 2.9), 7 (6%) fulfilled criteria for DLB (MMSE, 24.0 6 6.6), 5 (5%) fulfilled criteria for PD (MMSE, 27.4 6 2.7), and 4 (4%) fulfilled criteria for VaD (MMSE, 27.8 6 2.1). No serious adverse events related to the study drug were observed or reported by any participants as a result of the 18 F-florbetaben scans, even when low SAs were used. There were no significant fluctuations of hematology, biochemistry, coagulation profile, and vital signs in any subject from prescan laboratory blood samples and 1-wk postscan laboratory blood samples. No participant or any of their relatives raised concerns about the study, and all enrolled participants tolerated the study well.
All AD patients except for 1 showed extensive cortical 18 F-florbetaben retention that was greater in the frontal and posterior cingulate or precuneus cortex and slightly less in the lateral temporal and parietal cortex (Fig. 2 ). Similar to what was observed in 11 C-PiB studies, there was relative sparing of primary sensorimotor cortex, with no appreciable binding in the cerebellar cortex. High retention in white matter was observed in all groups.
Twenty-seven controls presented no cortical or subcortical gray-matter 18 F-florbetaben binding, and their scans were clearly distinguishable from patients with AD ( Fig. 1) . However, 5 (16%) controls were classified as having mild to diffuse cortical 18 F-florbetaben binding involving the orbitofrontal and cingulate or precuneus regions, in a pattern similar to that observed in AD and that resembled the early stages of Ab deposition described by Braak and Braak (28) .
Cortical 18 F-florbetaben binding was present in 12 (60%) of 20 MCI subjects (Fig. 2) , with some of their PET scans visually indistinguishable from AD patients. Conversely, 8 MCI subjects showed only white-matter retention and were visually indistinguishable from controls. All 5 PD, 3 of 4 VaD, 10 of 11 FTLD, and 5 of 7 DLB patients had low cortical 18 F-florbetaben binding (Fig. 2) . One FTLD patient showed mild frontal binding of 18 F-florbetaben, whereas 2 DLB patients presented with cortical binding with a distribution similar to that of AD. However, when present, the degree of 18 F-florbetaben binding in the DLB patients was generally lower than that observed in AD (Fig. 3) . One VaD patient presented with a PET scan indistinguishable from AD.
As previously reported, distribution volume ratio (DVR) values derived from dynamic data correlated strongly with SUVR in all cortical regions, with r 5 0.98 and P , 0.0001 for the mean neocortical measure (14) . Therefore, SUVR calculated from the data acquired over the 90-to 110-min postinjection interval are reported here.
Neocortical SUVR in controls was 1.26 6 0.2, compared with 1.93 6 0.3 in AD patients (P , 0.0001, effect size d 5 2.8). The box plot in Figure 3 shows the neocortical SUVR for all groups examined. Applying the cutoff SUVR of 1.4, 5 (16%) controls were considered to have high Ab burden. The 5 PD patients had low neocortical SUVR, with no overlap with the AD patients. There was also good separation between the AD and FTLD groups, despite 1 high 18 F-florbetabenbinding FTLD and 1 low 18 F-florbetaben-binding AD patient (Fig. 3) . Although 63% of the amnestic MCI subjects presented with high 18 F-florbetaben binding, the nonamnestic MCI subjects showed low 18 F-florbetaben binding.
All gray-matter regions in the AD group were significantly higher than in controls. Table 2 lists the regional SUVR for all groups. In the MCI group, the posterior cingulate, parietal, temporal, and frontal cortices and the striatum were significantly higher than in controls. No regional differences were observed between controls and the other groups examined.
ROC analysis of the visual reading of the AD and control 18 F-florbetaben PET images obtained 90-110 min after injection against clinical diagnosis yielded an area under the curve (AUC) of 0.92, with a sensitivity of 97% and a specificity of 88%. Semiquantitative analysis yielded an AUC of 0.91, with a sensitivity of 97% and a specificity of 84%. ROC analysis of the visual reading and semiquantitative analysis from the AD and FTLD patients yielded an AUC of 0.92, with a sensitivity of 97% and a specificity of 91%. When the same analysis was performed with the MCI subjects, AUCs of 0.74 and 0.80 were obtained against controls or AD participants, respectively.
There was no effect on scan appearance or neocortical SUVR from lowering the SA of 18 F-florbetaben (1.9 6 0.2 GBq/mmol to 58.4 6 27.5 GBq/mmol) in the subgroup of 8 AD patients and 8 controls who underwent repeated scans. Neocortical SUVR measured 1.32 6 0.22 and 1.32 6 0.25 (P 5 0.71) for the 8 controls in the high-and low-SA scans, respectively, whereas in the 8 AD patients the neocortical SUVR measured 1.89 6 0.36 and 1.91 6 0.31 (P 5 0.65) in the high-and low-SA scans, respectively. Test-retest variability for neocortical SUVR was 6.2% (range, 0.6%-12.2%; median, 6.6%) in AD patients and 2.9% (range, 0.1%-9.0%; median, 2.8%) in controls, with a combined variability of 4.6% for the whole subgroup.
Although there were no correlations between age and neocortical SUVR in the groups examined, a trend was observed in the control group (r 5 0.32, P 5 0.09). No differences were observed in neocortical SUVR between men and women when all groups were considered together. When examined separately, and although there were no differences in age and MMSE, male AD patients had significantly higher neocortical SUVR than their female counterparts (2.12 6 0.26 vs. 1.78 6 0.23, P 5 0.001). Neocortical SUVR correlated inversely with MMSE when all groups were analyzed together (r 5 20.49, P , 0.0001) and only in the MCI group when examined separately (r 5 20.76, P , 0.0001). There was no correlation in the AD or FTLD groups between neocortical SUVR and time elapsed between onset of cognitive impairment and development of the
DISCUSSION
This is the first report, to our knowledge, in which 109 participants encompassing a wide range of dementing and nondementing neurodegenerative diseases were evaluated with an 18 F-labeled Ab imaging radiotracer. The studies were designed to assess the specificity of 18 F-florbetaben to detect AD pathology in clinically well-characterized cases.
The AD group showed higher Ab burden, as defined by 18 F-florbetaben binding, than did controls, in accordance with previous reports using 18 F-florbetaben or other amyloid tracers (2,3,14-16 ). Only 1 of the 30 participants classified as AD had low 18 F-florbetaben binding. A potential limitation of our study is the reliance on clinical diagnosis as the gold standard rather than neuropathology. Thus, our finding may be attributable to incorrect clinical diagnosis because, even in highly specialized centers, the accuracy of clinical diagnosis, compared with postmortem histopathologic diagnosis, is around 85%-90% (29) (30) (31) .
In contrast with our previous reports using 11 C-PiB (27), the relationship between age and neocortical SUVR in controls did not reach significance, most likely attributable to the low number of controls with elevated 18 F-florbetaben binding. On the other hand, and in agreement with that same report (27) , the Ab burden in AD patients was significantly higher in men than in women, suggesting that for similar cognitive impairment, women may be more susceptible to the effects of Ab, requiring a lower Ab burden to manifest dementia.
Only 16% of controls were deemed positive for Ab in these studies. As in numerous reports, this finding suggests that Ab deposition is an early feature of the disease preceding cognitive impairment. On the other hand, the prevalence of positive scans is slightly lower than the 20%-30% of positive scans in healthy elderly individuals reported using 11 C-PiB (2, 4, 32, 33) and with postmortem studies that have documented moderate numbers of Ab plaques in the cerebral cortex of about a quarter of nondemented persons aged over 75 y (34, 35) . Our findings are in accordance with previous reports using 11 C-PiB in MCI (60% positive) and FTLD (9% positive) (2, 5) . As with 11 C-PiB, 18 F-florbetaben PET appears to be an excellent test for distinguishing FTLD from AD. Ongoing longitudinal studies will determine whether the 2 well-differentiated clusters of 18 F-florbetaben binding in the MCI group can reliably predict those who will progress to AD or other causes of dementia. All PD patients and 5 of the 7 DLB patients showed low 18 Fflorbetaben binding. The findings in the DLB group are somewhat at odds with previous reports using 11 C-PiB, in which more than 50% of the DLB patients showed Ab deposition (36, 37) , though postmortem reports have shown wide variation where between 30% and 90% of DLB patients have shown Ab plaques at autopsy (38) . Conversely, and as we previously reported (2), there seems to be a strong association between rapid development of the full DLB phenotype and Ab burden, with evidence that Ab exacerbates a-synuclein-dependent neuronal injury (39) . Therefore, strategies aimed at reducing Ab in AD may also be beneficial in DLB patients.
Although the cortical distribution of 18 F-florbetaben is almost identical to that reported for 11 C-PiB, the degree of binding is slightly less. 18 F-florbetaben neocortical SUVR for AD was 53% greater than in controls. Our previously reported experience with 11 C-PiB, using the same equipment and semiquantitative methods, is that on average 11 C-PiB binding is 60%-70% higher in AD patients than in controls (2, 27) . Despite this, 18 F-florbetaben yielded a slightly larger effect size (2.8 vs. 2.2) probably because of the lower prevalence of high Ab burden in the control group (33% vs. 16% for 11 C-PiB and 18 F-florbetaben, respectively). When compared with the available data from the other 18 F compounds (15, 16) , the effect size for 18 Fflutemetamol (2.7) and 18 F-florbetapir (2.3) is slightly lower than for 18 F-florbetaben.
Another important factor that might explain the slight discrepancy in specificity favoring the visual assessment over the semiquantitative approach is the degree of nonspecific binding to white matter. All 18 F compounds show higher nonspecific binding to white matter than 11 C-PiB. Although the ratios of frontal cortex to white matter for PiB are 0.8, 1.1, and 1.3 in controls, MCI, and AD, respectively (27) , the same ratios for 18 F-florbetaben (0.7, 0.8, and 1.1), 18 F-flutemetamol (0.4, 0.5, and 0.7) (16), and 18 Fflorbetapir (0.7 and 1.1 for controls and AD, respectively) (15) are lower.
The distribution of 18 F-florbetaben binding matched the postmortem distribution of neuritic plaques in AD (28) , providing a robust separation of AD patients from controls and from patients with FTLD or PD. This separation was achieved either with visual image inspection or a simple semiquantitative measure derived from a short scan at 90 min after injection of the tracer. These findings suggest that 18 F-florbetaben PET can be used in clinical practice, with a short scan easily tolerated by elderly patients while allowing economical use of a PET camera. Furthermore, the decay half-life of 18 F makes centralized production with distribution to multiple PET sites possible, thereby improving access to Ab imaging, enabling early and more accurate diagnosis of AD and the ability to conduct and monitor large-scale, multicenter, therapeutic clinical trials and simultaneously reducing the cost. Moreover, the reproducibility of the 18 F-florbetaben scans was estimated to be approximately 5%, even when 25 times greater amounts of cold florbetaben were injected, suggesting that within a wide range of SAs 18 F-florbetaben is a reliable tool for the in vivo assessment of Ab deposition.
As observed with 11 C-PiB (2), only when all groups were considered together was there a correlation between neocortical SUVR and MMSE-a correlation driven by the low Ab burden in controls at one end and the high Ab burden in AD at the other. We did not find a correlation between the Ab burden and MMSE in the AD cases, in agreement with our previous reports with 11 C-PiB (2), and with postmortem studies that have not consistently demonstrated a relationship between the density of Ab plaques and the severity of dementia (35, 40, 41) . Our data suggest that Ab deposition is an early event and likely to occur before demonstrable cognitive impairment. Similar to what has been reported using 11 C-PiB (9), a correlation between 18 F-florbetaben binding and cognitive impairment was observed in MCI subjects. This finding has not been consistent (25) , especially when only amnestic MCI subjects are examined. In the present sample, 20% of the MCI participants were classified as nonamnestic, and they presented with no Ab burden, therefore driving the correlation between MMSE and 18 F-florbetaben binding within the MCI group. Another important aspect is that 37% of amnestic MCI subjects did not have elevated 18 F-florbetaben binding, suggesting that subject selection for antiamyloid therapeutic trials in MCI by current clinical criteria will include a large proportion of subjects that are unlikely to have AD pathology.
Longitudinal Ab imaging studies have shown that Ab deposition is associated with a higher risk of cognitive decline in controls and MCI, denoting the nonbenign nature of Ab deposition (10, 42) . Therefore the specificity of Ab imaging with 18 F-florbetaben for detection of AD is likely to increase with longer follow-up of study participants. Longitudinal follow-up will also determine the value of 18 F-florbetaben PET for detection of prodromal and even preclinical AD (10, 27) . Ab imaging is a tool that will open up new possibilities for early intervention and prevention of dementia due to AD. Ab imaging is likely to play a critical role in the development of antiamyloid therapies by improving patient selection at early phases of the disease and monitoring treatment response.
CONCLUSION
Our results demonstrate that 18 F-florbetaben can reliably detect Ab deposition in the brain and is thereby useful in the early and differential diagnosis of AD from other dementing or nondementing neurodegenerative conditions. 18 F-florbetaben provides images similar to those provided by 11 C-PiB, without the limitation of the short 11 C radioactive decay half-life that precludes the application of PiB in clinical practice. Longitudinal studies with 18 Fflorbetaben will provide information on the rate of Ab deposition, further clarifying the relationship between Ab accumulation and cognitive decline and asserting the value of Ab imaging as a predictor of cognitive decline and progression to clinical Alzheimer disease.
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